-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Background: Anti-spiking monoclonal antibodies against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) provided some of the first highly effective treatments for outpatients with young to moderate coronavirus disease 2019 (COVID-19)
.
These therapies have convincingly demonstrated a reduction in progression to severe disease and hospitalization, and recent data suggest a reduction in mortality.
Anti-spiking monoclonal antibodies against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) offer some of the first highly effective treatments for outpatients with young to moderate coronavirus disease 2019 (COVID-19)
Methods: The same efficacy as when the beta variant was dominant when they were first evaluated and approved
.
We used a retrospective cohort to compare the incidence of severe outcomes compared with delta during periods when alpha and beta were dominant
RESULTS: A total of 5356 patients received infusions during the alpha/beta variant-dominant (n=4874) and delta-variant-predominant (n=482) eras
.
Overall, the odds of serious infection were 3.
Figure 1.
Time and geographical trends of severe COVID-19 after anti-spike monoclonal antibody therapy
.
ARZ, AZ; FL, FL; mAb, monoclonal antibody; MCHS, Mayo Clinic Health System; RST, Rochester
Figure 1.
Figure 2.
Incidence of severe COVID-19 following anti-spike mAb therapy during possible alpha/beta and delta periods
.
Incidence of severe COVID-19 following anti-spike mAb therapy during possible alpha/beta and delta periods
.
CONCLUSIONS: Although the possibility of reduced effectiveness of anti-Spike mAbs in the clinical setting cannot be ruled out, the higher odds of serious infection may be due to the more virulent delta variant
.
There is a need to investigate the most effective strategies for using and improving anti-spiking monoclonal antibodies to treat emerging variants
Although the possibility of reduced effectiveness of anti-spike mAbs in the clinical setting cannot be ruled out, the higher odds of serious infection may be due to the more virulent delta variant
Effectiveness of Monoclonal Antibodies in Preventing Severe COVID-19 With Emergence of the Delta Variant.
Leave a Comment here
